Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.59 |
| ▸ | PPARA | Q07869 | 5/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6424101 | 0.95 | PPARG (0.55) | PPARGPPARAAKR1C3AKR1C2 | |
| SCHEMBL6423525 | 0.93 | PPARG (0.57) | PPARGPPARAAKR1C3AKR1C2LMNA | |
| SCHEMBL6425804 | 0.91 | PPARG (0.51) | PPARGPPARAAKR1C3AKR1C2 | |
| SCHEMBL6426960 | 0.91 | PPARG (0.51) | PPARGPPARAAKR1C3AKR1C2 | |
| SCHEMBL6425006 | 0.88 | AKR1C3 (0.52) | PPARGPPARAAKR1C3AKR1C2LMNA | |
| SCHEMBL6422484 | 0.88 | PPARG (0.48) | PPARGPPARAAKR1C3AKR1C2 | |
| SCHEMBL5560601 | 0.87 | PTGS2 (0.52) | PPARGPPARAAKR1C3AKR1C2LMNA | |
| SCHEMBL6426639 | 0.86 | PPARG (0.58) | PPARGPPARAAKR1C3AKR1C2LMNA | |
| SCHEMBL6425912 | 0.85 | PPARG (0.48) | PPARGPPARAAKR1C3AKR1C2 | |
| SCHEMBL6426691 | 0.85 | PPARG (0.46) | PPARGPPARAAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | PPARG 1908/4885PPARA 2460/4885AKR1C3 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.